Abstract: A refrigeration apparatus has a refrigerant. The refrigerant is a non-azeotropic refrigerant mixture containing 50% by weight or more and 80% by weight or less of a high-boiling point refrigerant, 10% by weight or more and less than 50% by weight of a medium-boiling point refrigerant having a boiling point lower than that of the high-boiling point refrigerant, and 20% by weight or less of a low-boiling point refrigerant having a boiling point lower than that of the medium-boiling point refrigerant. The content of the high-boiling point refrigerant is larger than that of the medium-boiling point refrigerant, and the content of the medium-boiling point refrigerant is larger than that of the low-boiling point refrigerant. Piping through which the refrigerant derived from the compressor and flowing into the condenser passes includes a countercurrent flow configurator in which the refrigerant flowing through the piping is countercurrent to the cooling air.

Abstract: Provided is a method for assisting in grasping the status of platelet activation, by developing a biomarker that more accurately reflects platelet activation in vivo, said method being usable in testing for thrombotic hemostatic diseases. The method for assisting in grasping the status of platelet activation comprises (1) measuring the concentration of soluble CLEC-2 and a platelet count in a sample obtained from a subject, and (2) calculating a value of [soluble CLEC-2 concentration]/[platelet count] by dividing the soluble CLEC-2 concentration by the platelet count. If desired, the method may further comprise (3) comparing the value with a value of [soluble CLEC-2 concentration]/[platelet count] obtained by using samples from healthy persons.

Abstract: An information management apparatus includes at least one processor configured to acquire first time information and second time information, the first time information being related to a time taken to acquire a predetermined amount of at least one or more specific nucleic acids based on a first cell acquired from a cancer patient, the second time information being related to a time taken to culture a second cell different from the first cell until a predetermined amount is reached; and store individual patient information in which the first time information and the second time information are associated with attribute information of the cancer patient.

Abstract: A nanoparticle body comprising: a metallic nanoparticle; a polymer film covering a surface of the metallic nanoparticle; a specifically bondable substance that specifically bonds to a test substance in a specimen; and a fluorescent substance labeled on a surface of the polymer film or on the specifically bondable substance, wherein the fluorescent substance is excited by light having a luminous wavelength of plasmon resonance in a composite in which two or more of the nanoparticle body are bonded together with the test substance interposed therebetween.

Abstract: A composite analysis device, configured to perform a plurality of types of analyses, which prevent a shortage of a volume of a specimen. The analysis device can execute a plurality of measurement processing steps for a biological sample based on order information. The analysis device includes: a pierce nozzle unit which pierces a hole in a sealed sample container in which the biological sample is contained, collects the biological sample, and discharges the biological sample into a predetermined containing unit; a sample nozzle unit which dispenses the biological sample contained in the containing unit into one or more cuvettes; and a control device which control operations of the pierce nozzle unit and the sample nozzle unit based on the order information.

Abstract: The present invention relates to a method for diagnosis of a cardiovascular disease or condition or atherosclerosis and for a method for evaluating the risk of a subject of developing the same. Methods are further provided for evaluating a subject's risk of mortality, for evaluating whether a subject will benefit from a certain treatment or whether a subject needs to be hospitalized or whether a subject may be discharged. The present invention provides sCD14 or a fragment or derivative thereof (including in particular sCD14-ST) as a novel marker for cardiovascular risk in general, more specifically as a marker for cardiovascular disease or condition, or atherosclerosis.

Abstract: An atomization device according to the present invention is provided with: a main body part which has a container space that contains a hydrogen peroxide solution; and a diaphragm which is provided with through holes where the hydrogen peroxide solution contained in the container space passes, and which atomizes the hydrogen peroxide solution passing through the through holes.

Abstract: Provided is a non-specific reaction inhibitor that has high solubility, can be added in sufficient amounts, is inexpensive, and has small variation among different lots. The non-specific reaction inhibitor of the present invention comprises a complex of a peptide or nucleic acid molecule that specifically binds to a non-specific reaction substance and a polymer compound.

Abstract: This culture device comprises: an inner box having a culture space formed on the inside thereof; an outer box which covers the outside of the inner box with a first space formed therebetween; a CO2 sensor which is positioned in the first space and has a first end thereof exposed to the culture space; and a restricting member which restricts the flow of a fluid towards the CO2 sensor within the first space.

Abstract: Provided are an immunoassay reagent and an immunoassay method for elastase 1 (E1) present in human fecal samples, which is simple and can handle a large number of samples without requiring special facilities or equipment, can analyze in a short time so as to be suitable for emergency testing, and can quantitatively analyze a wide range of concentrations from low to high. The immunoassay method, comprising: (a) adding ?1-antitrypsin (?1AT) to a fecal sample obtained from a subject; (b) incubating the fecal sample and reacting E1 with ?1AT to form a complex; (c) incubating the fecal sample with a solution containing a carrier on which an immunological partner capable of recognizing the E1-?1AT complex is immobilized; and (d) analyzing a change caused by the reaction between the E1-?1AT complex and the immunological partner.

Abstract: This culture device comprises: a duct having an inner wall surface which faces a culture space, and a mounting surface which faces the portion to be mounted to of the inner surface, the mounting surface being mounted to the portion to be mounted to, and an air passage being formed with the inner wall surface; and a microbial light source provided within the passage. A protrusion which comes into close contact with the mounting surface, and which protrudes towards the mounting surface, is formed on the portion to be mounted to, or a protrusion which comes into close contact with the portion to be mounted to and which protrudes towards the portion to be mounted to is formed on the mounting surface.

Abstract: Provided are a novel biomarker that can conveniently detect a tubulointerstitial disorder or that can grasp the disease state of a kidney disease using a urine sample, and a use thereof. The biomarker is scd14-st in urine.

Abstract: This cold storage is provided with: a first sliding door that opens/closes a cold chamber; a second sliding door that opens/closes the cold chamber, and is positioned between the cold chamber and the first sliding door when the cold chamber is fully open; a compressor disposed at a position that becomes closer to the closed end of the second sliding door than the closed end of the first sliding door when the cold chamber is fully closed; a fan that generates air flow passing the surroundings of the compressor; and a housing that accommodates the compressor, and has formed therein a blow port for blowing out the air flow toward the first sliding door and the second sliding door.

Abstract: The purpose of the present invention is to develop a biomarker that better reflects thrombus formation in vivo, and to provide a method that enables risk assessment of cancer-associated thrombosis in the perioperative period of cancer patients. The method includes a step of measuring the concentration of soluble CLEC2 in blood collected from the cancer patients.

Abstract: Provided is a convenient, rapid, and objective blood test-based risk evaluation method for the diagnosis of tia that can complement the clinical symptom interview, and provided is a convenient, rapid, and objective blood test-based risk evaluation method for the differential diagnosis of cardiogenic and non-cardiogenic acute cerebral vascular diseases such as cerebral infarction and tia that can complement imaging, electrocardiogram, and conventional blood tests. The concentration of soluble clec2 is measured in the blood collected from a patient.

Abstract: In the treatment of hemorrhagic stroke, provided is a means for conveniently complementing the diagnosis by blood tests. The method comprises a step of measuring (or determining) the concentration of soluble clec2 (or a value obtained by dividing the soluble clec2 concentration by platelet counts) present in blood collected from a patient suspected of having hemorrhagic stroke or a patient diagnosed with hemorrhagic stroke.

Abstract: Provided is a cold storage including: a sliding door; a lower frame for guiding a lower side of the sliding door, the lower frame having a recessed part; an upper frame for guiding an upper side of the sliding door; and a first sealing member having a first attachment part, which is a portion attached to the sliding door, and a first tip-end. A cross-sectional shape of the first sealing member is an arcuate shape. The first attachment part is located at the uppermost side of the first sealing member. The first tip-end is located at the lowermost side of the first sealing member. When a wheel of the sliding door drops into the recessed part, an outer peripheral surface of the first sealing member is brought into close contact with the upper frame or the lower frame.

Abstract: This seal structure of a cold storage comprises: a long member that has a magnetic portion configured from a magnetic material; and packing having a magnet that attracts and is attracted by the magnetic portion, a holding portion that holds the magnet, and a sealing portion that comes into close contact with the long member at a position further inward or outward of a cooling chamber than the holding portion when the cooling chamber is sealed, the packing increasing the distance between one portion of the magnet and the long member prior to increasing the distance between the other portion of the magnet and the long member during separation from the long member.